Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Status unconfirmed · Phase 2

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Vaccines made from a patient's dendritic cells may make the body build an immune response to kill tumor cells. It is not yet known whether combining vaccine therapy with either gp100 antigen or the patient's tumor cells will cause a stronger immune response and kill more tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy and gp100 antigen to see how well they work compared to vaccine therapy and patient's tumor cells in treating patients with stage III or stage IV melanoma.

Key facts

Study ID

NCT00085397

Run by

Dana-Farber Cancer Institute

People needed

40

Starts

2004-03-01

Last updated by the study team

2009-02-09

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.